📰 Merck Research Program News
Merck Research Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Merck Research Program. Real-time updates on events, politics, business and more.
May 24, 2022
/PRNewswire/ -- Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today...
March 8, 2021
KEYTRUDA ® is an anti-PD-1 therapy that works by helping increase the ability of the bodys immune system to help detect and fight tumour cells. 1 An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily. 2 KIRKLAND, QC, March 8, 2021 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Health Canada has approved KEYTRUDA ® (pembrolizumab), Mercks anti-PD-1 therapy, for the first...
March 8, 2021
Approval Based on Significant Progression Free Survival Findings from Phase 3 KEYNOTE-177 Trial KEYTRUDA ® is an anti-PD-1 therapy that works by helping increase the ability of the body’s immune system to help detect and fight tumour cells. 1 An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily. 2 Merck known as MSD outside the United States … Approval Based on Significant Progression Free Survival Findings from Pha...